Effect on Acetaminophen Metabolism by Liquid Formulations
Primary Purpose
Acetaminophen Metabolism, Acetaminophen Poisoning, Drug Metabolism by Excipients
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Acetaminophen liquid formulation
Acetaminophen solid formulation
Sponsored by
About this trial
This is an interventional other trial for Acetaminophen Metabolism focused on measuring acetaminophen, excipients
Eligibility Criteria
Inclusion Criteria:
- Healthy volunteer ages 18-40
- Not taking any chronic medications
Exclusion Criteria:
- Pregnancy
- Any history of liver disease
- Frequent alcohol use (2 or more drinks more than 4 times per week)
- Unable to provide informed consent
Sites / Locations
- Harvard - Thorndike Clinical Research Center at Beth Israel Deaconess Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Acetaminophen solid formulation
Acetaminophen liquid formulation
Arm Description
Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
Outcomes
Primary Outcome Measures
Acetaminophen Metabolites
Area-under-curve from time zero to 8 hours for APAP-cysteinate metabolite. Serum was collected just prior to and at hours 1, 2, 4, 6, and 8 after administration of the APAP dose.
Secondary Outcome Measures
Full Information
NCT ID
NCT01246713
First Posted
November 22, 2010
Last Updated
March 28, 2017
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Harvard University, National Center for Research Resources (NCRR)
1. Study Identification
Unique Protocol Identification Number
NCT01246713
Brief Title
Effect on Acetaminophen Metabolism by Liquid Formulations
Official Title
Effect on Acetaminophen Metabolism by Liquid Formulations: Do Excipients in Liquid Formulation Prevent Production of Toxic Metabolites?
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
July 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Harvard University, National Center for Research Resources (NCRR)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether excipients in the liquid formulation of acetaminophen prevent the formation of the toxic metabolites of acetaminophen.
Detailed Description
Acetaminophen (APAP) poisoning is the most frequent cause of acute hepatic failure in the United States. Toxicity requires cytochrome P-450 bioactivation of APAP. Children are less susceptible to APAP toxicity; the current theory is that they have different metabolism than adults. However, children's liquid preparations of APAP contain excipients which have been shown to inhibit APAP bioactivation in vitro and in rodents. Children tend to ingest liquid preparations, which could potentially explain their decreased susceptibility instead of an intrinsically different metabolism. Further, our review of Poison Center epidemiologic data shows that liquid preparations are less toxic in adults. Our hypothesis is that excipients in liquid preparations inhibit the bioactivation of APAP. The design is a pharmacokinetic cross-over study in humans. Healthy adult subjects will be recruited for administration of therapeutic doses of APAP in capsule and liquid formulations. Plasma via a heplock will be collected at serial time points up to 8 hours and assayed for APAP and its metabolites. After a washout period, subjects will receive the same dose of APAP in the alternate preparation. The pattern of metabolites, indicating the activity of the bioactivating enzymes, will be compared. A significant difference in P-450 metabolites will support the hypothesis and provide preliminary data for studies in patients who have ingested potentially toxic doses of APAP. Ultimately, this work could support development of novel antidotal therapy for APAP overdose.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acetaminophen Metabolism, Acetaminophen Poisoning, Drug Metabolism by Excipients
Keywords
acetaminophen, excipients
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Acetaminophen solid formulation
Arm Type
Placebo Comparator
Arm Description
Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
Arm Title
Acetaminophen liquid formulation
Arm Type
Active Comparator
Arm Description
Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
Intervention Type
Drug
Intervention Name(s)
Acetaminophen liquid formulation
Intervention Description
Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
Intervention Type
Drug
Intervention Name(s)
Acetaminophen solid formulation
Intervention Description
Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
Primary Outcome Measure Information:
Title
Acetaminophen Metabolites
Description
Area-under-curve from time zero to 8 hours for APAP-cysteinate metabolite. Serum was collected just prior to and at hours 1, 2, 4, 6, and 8 after administration of the APAP dose.
Time Frame
8 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy volunteer ages 18-40
Not taking any chronic medications
Exclusion Criteria:
Pregnancy
Any history of liver disease
Frequent alcohol use (2 or more drinks more than 4 times per week)
Unable to provide informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Ganetsky, MD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Harvard - Thorndike Clinical Research Center at Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
23436315
Citation
Ganetsky M, Bohlke M, Pereira L, Williams D, LeDuc B, Guatam S, Salhanick SD. Effect of excipients on acetaminophen metabolism and its implications for prevention of liver injury. J Clin Pharmacol. 2013 Apr;53(4):413-20. doi: 10.1002/jcph.24. Epub 2013 Feb 22.
Results Reference
derived
Learn more about this trial
Effect on Acetaminophen Metabolism by Liquid Formulations
We'll reach out to this number within 24 hrs